# SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

> **NCT00002657** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 20 (actual)

## Conditions studied

- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** bleomycin sulfate
- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** cyclophosphamide
- **DRUG:** cytarabine
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** methotrexate
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate
- **PROCEDURE:** conventional surgery
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00002657
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-05
- **Primary completion:** 2003-11
- **Final completion:** 2011-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2013-01-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002657, "SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*